| 1 |
GBD 2017 Oesophageal Cancer Collaborators．The global，regional，and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017[J]．Lancet Gastroenterol Hepatol，2020，5（6）：582-597．
|
| 2 |
Haverkamp L，Seesing MF，Ruurda JP，et al．Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer[J]．Dis Esophagus，2017，30（1）：1-7．
|
| 3 |
Sugita S，Kinoshita T，Kuwata T，et al．Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type II adenocarcinoma of the esophagogastric junction[J]．Surg Endosc，2021，35（1）：340-348．
|
| 4 |
言成一，陈龙奇．回眸2019——聚焦食管胃结合部肿瘤的外科治疗[J]．中华胃肠外科杂志，2020，23（1）：20-25．
|
| 5 |
Barbour AP，Rizk NP，Gonen M，et al．Adenocarcinoma of the gastroesophageal junction：influence of esophageal resection margin and operative approach on outcome[J]．Ann Surg，2007，246（1）：1-8．
|
| 6 |
Mine S，Kurokawa Y，Takeuchi H，et al．Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors[J]．Eur J Surg Oncol，2015，41（10）：1348-1353．
|
| 7 |
国际食管疾病学会中国分会（CSDE）食管胃结合部疾病跨界联盟，中国医师协会内镜医师分会腹腔镜外科专业委员会，中国医师协会外科医师分会上消化道外科医师专业委员会，等．食管胃结合部腺癌外科治疗中国专家共识（2018年版）[J]．中华胃肠外科杂志，2018，21（9）：961-975．
|
| 8 |
Kurokawa Y，Takeuchi H，Doki Y，et al．Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors：A Prospective Nationwide Multicenter Study[J]．Ann Surg，2021，274（1）：120-127．
|
| 9 |
Yamashita H，Seto Y，Sano T，et al．Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma[J]．Gastric Cancer，2017，20（Suppl 1）：69-83．
|
| 10 |
Matsuda T，Kurokawa Y，Yoshikawa T，et al．Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma：A Retrospective Multicenter Study[J]．World J Surg，2016，40（7）：1672-1679．
|
| 11 |
中华医学会外科学分会腹腔镜与内镜外科学组．Siewert Ⅱ型食管胃结合部腺癌腔镜手术治疗中国专家共识（2019版）[J]．中国实用外科杂志，2019，39（11）：1129-1135．
|
| 12 |
Chen Y，Zhao XK，Xu RH，et al．Transthoracic，thoracoabdominal，and transabdominal surgical approaches for gastric cardia adenocarcinomas：a survival evaluation based on a cohort of 7103 patients[J]．World J Surg Oncol，2022，20（1）：217．
|
| 13 |
Yin Q，Wang W，Liu H，et al．Clinical application and observation of modified Ivor-Lewis surgery in Siewert type II adenocarcinoma of the Esophagogastric junction[J]．J Cardiothorac Surg，2019，14（1）：207．
|
| 14 |
Kamarajah SK，Phillips AW，Griffiths EA，et al．Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction （GEJ） Adenocarcinoma? A Registry-Based Analysis[J]．Ann Surg Oncol，2021，28（13）：8485-8494．
|
| 15 |
Blank S，Schmidt T，Heger P，et al．Surgical strategies in true adenocarcinoma of the esophagogastric junction（AEG II）：thoracoabdominal or abdominal approach?[J]．Gastric Cancer，2018，21（2）：303-314．
|
| 16 |
Kneuertz PJ，Hofstetter WL，Chiang YJ，et al．Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy：Do Thoracic and Abdominal Approaches Differ?[J]．Ann Surg Oncol，2016，23（2）：626-632．
|
| 17 |
Zhu K，Xu Y，Fu J，et al．Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction：A Comprehensive Analysis of Data from the SEER Registry[J]．Dis Markers，2019，2019：9637972．
|
| 18 |
Straatman J，van der Wielen N，Cuesta MA，et al．Minimally Invasive Versus Open Esophageal Resection：Three-year Follow-up of the Previously Reported Randomized Controlled Trial：the TIME Trial[J]．Ann Surg，2017，266（2）：232-236．
|
| 19 |
Li KK，Bao T，Wang YJ，et al．The Postoperative outcomes of thoracoscopic-laparoscopic Ivor-Lewis surgery plus D2 celiac lymphadenectomy for patients with adenocarcinoma of the esophagogastric junction[J]．Surg Endosc，2020，34（11）：4957-4966．
|
| 20 |
Suzuki S，Kanaji S，Urakawa N，et al．Survival Benefit of Neoadjuvant Chemotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction[J]．Cancer Diagn Progn，2021，1（3）：185-191．
|
| 21 |
Shapiro J，van Lanschot JJB，Hulshof MCCM，et al．Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer （CROSS）：long-term results of a randomised controlled trial[J]．Lancet Oncol，2015，16（9）：1090-1098．
|
| 22 |
Ahmad MU，Javadi C，Poultsides GA．Neoadjuvant Treatment Strategies for Resectable Proximal Gastric，Gastroesophageal Junction and Distal Esophageal Cancer[J]．Cancers （Basel），2022，14（7）：1755．
|
| 23 |
Zhu M，Chen C，Foster NR，et al．Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction[J]．Clin Cancer Res，2022，28（14）：3021-3031．
|
| 24 |
Tang Z，Wang Y，Liu D，et al．The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction[J]．Nat Commun，2022，13（1）：6807．
|
| 25 |
国家癌症中心食管癌多学科协作组，中华医学会胸心血管外科学分会食管疾病学组，中国医师协会胸外科医师分会食管外科专家委员会．中国食管癌围手术期免疫治疗专家共识（2021年）[J]．中华胸部外科电子杂志，2022，9（1）：12-22．
|